Article
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2025
Swalduz Aurélie, Beau-Faller Michèle, Planchard David, Mazieres Julien, Bayle-Bleuez Sophie, Debieuvre Didier, Fallet Vincent, Geier Margaux, Cortot Alexis, Couraud Sébastien, Daniel Catherine, Domblides Charlotte, Pichon Eric, Fabre Elizabeth, Larivé Sébastien, Lerolle Ulrike, Tomasini Pascale, Wislez Marie, Missy Pascale, Morin Franck, Westeel Virginie, Auliac Jean-Bernard
Abstract excerpt
BACKGROUND: BRAF V600E mutations occur in 2-5 % of advanced non-small cell lung cancer (NSCLC) patients. The dabrafenib-trametinib (D-T) combination was associated with improved and durable OS in patients in phase II. This study (IFCT-2004 BLaDE study) reported the efficacy of D-T combination in a large retrospective French real-world multicenter cohort of patients with advanced BRAF V600E-mutated NSCLC. METHOD:...
Topics
Join the communities discussing this publication.